These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16312640)

  • 1. Effect of combination therapy with ciprofloxacin and azlocillin in intensive care patients with pneumonia and/or sepsis.
    Engelhardt D; Ruckdeschel G
    J Chemother; 1989 Jul; 1(4 Suppl):788-9. PubMed ID: 16312640
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of bronchopulmonary infections by ciprofloxacin in an intensive care unit. Correlation between serum and bronchial concentrations and bacteriological results.
    Beuscart C; Leroy O; Chidiac C; Houriez S; Caillaux M; Beaucaire G; Mouton Y
    J Chemother; 1989 Jul; 1(4 Suppl):794-6. PubMed ID: 16312643
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical and pharmacoeconomic perspective use of amoxicillin/sulbactam in the treatment of extra-hospital pneumonia].
    Sinopal'nikov AI; Zaĭtsev AA
    Voen Med Zh; 2006 Nov; 327(11):42-5. PubMed ID: 17300060
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa.
    Thauvin C; Lecomte F; Le Boete I; Grise G; Lemeland JF
    Infection; 1989; 17(1):31-4. PubMed ID: 2493429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.
    Gous A; Lipman J; Scribante J; Tshukutsoane S; Hon H; Pinder M; Mathivha R; Verhoef L; Stass H
    Int J Antimicrob Agents; 2005 Jul; 26(1):50-5. PubMed ID: 15955670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azlocillin versus azlocillin plus amikacin in the treatment of severe infections in intensive care unit patients.
    Mergoni M; Stocchetti N; De Cristofaro A; Antonioni M; Zuccoli P
    Chemioterapia; 1987 Aug; 6(4):286-9. PubMed ID: 3652280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hospital infections and problems of resistance today].
    Encke A; Knothe H
    Chirurg; 1985 Sep; 56(9):553-7. PubMed ID: 4053763
    [No Abstract]   [Full Text] [Related]  

  • 8. [Azlocillin plus amikacin: an alternative therapy for sepsis caused by resistant staphylococci?].
    Hernández ME; Ramos MJ; Ferrer NF
    Rev Panam Salud Publica; 2004 Nov; 16(5):315-9. PubMed ID: 15729980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriology profile among patients with ventilator-associated pneumonia from a medical intensive care unit at a tertiary care center in Mumbai.
    Set R; Bobade O; Shastri J
    Indian J Pathol Microbiol; 2011; 54(2):432-3. PubMed ID: 21623128
    [No Abstract]   [Full Text] [Related]  

  • 10. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU?
    Niederman MS
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1029-31. PubMed ID: 9351599
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
    Brückner O; Trautmann M
    J Chemother; 1989 Jul; 1(4 Suppl):782-3. PubMed ID: 16312637
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibiotic therapy for community-acquired pneumonia with septic shock: follow the guidelines.
    Blot S; Depuydt P
    Crit Care Med; 2007 Jun; 35(6):1617-8. PubMed ID: 17522537
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antibiotic strategies in the treatment of infection in critically ill patients].
    Schierbeck J; Kolmos HJ
    Ugeskr Laeger; 2007 Feb; 169(8):699-702. PubMed ID: 17313920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intensive care and neonatal septicemia].
    Storm W
    Anasthesiol Intensivmed Prax; 1977 Oct; 14(1):87-106. PubMed ID: 596605
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.
    Ulrich E; Trautmann M; Krause B; Bauernfeind A; Hahn H
    Infection; 1989; 17(5):311-5. PubMed ID: 2599653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment of septicaemia caused by P. aeruginosa with special reference to azlocillin.
    Shah PM
    Burns Incl Therm Inj; 1984 Oct; 11(1):65-71. PubMed ID: 6439386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
    Bassetti M; Righi E; Rosso R; Mannelli S; Di Biagio A; Fasce R; Pallavicini FB; Marchetti F; Viscoli C
    Int J Antimicrob Agents; 2006 Dec; 28(6):582-5. PubMed ID: 16979877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
    J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of ciprofloxacin plus azlocillin versus netilmicin plus azlocillin for the empirical treatment of fever in neutropenic patients.
    Hyatt DS; Rogers TR; McCarthy DM; Samson DS
    J Antimicrob Chemother; 1991 Aug; 28(2):324-6. PubMed ID: 1778867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.